[CMRX] Chimerix, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.75 Change: 0.2 (4.4%)
Ext. hours: Change: 0 (0%)

chart CMRX

Refresh chart

Strongest Trends Summary For CMRX

CMRX is in the medium-term down -56% below S&P in 1 year. In the long-term down -66% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company?s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 34.71% Sales Growth - Q/Q7.09% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.97% ROE-27.65% ROI
Current Ratio10.78 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-1578.72% Net Profit Margin-1582.88% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities700 K Cash From Investing Activities-54.72 M Cash From Operating Activities-18.84 M Gross Profit
Net Profit-22.27 M Operating Profit-22.33 M Total Assets274.12 M Total Current Assets177.26 M
Total Current Liabilities16.44 M Total Debt2.89 M Total Liabilities16.6 M Total Revenue1.24 M
Technical Data
High 52 week5.9 Low 52 week2.24 Last close2.93 Last change-3.3%
RSI74.42 Average true range0.19 Beta1.19 Volume236.01 K
Simple moving average 20 days6.72% Simple moving average 50 days-5.94% Simple moving average 200 days-27.88%
Performance Data
Performance Week-3.3% Performance Month-9.85% Performance Quart-20.6% Performance Half-38.19%
Performance Year-39.71% Performance Year-to-date14.01% Volatility daily4.88% Volatility weekly10.9%
Volatility monthly22.35% Volatility yearly77.41% Relative Volume181.52% Average Volume264.19 K
New High New Low

News

2019-03-07 12:24:00 | Should You Be Worried About Insider Transactions At Chimerix, Inc. NASDAQ:CMRX?

2019-03-05 16:09:29 | Edited Transcript of CMRX earnings conference call or presentation 5-Mar-19 1:30pm GMT

2019-03-05 07:00:00 | Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results

2019-03-04 08:00:00 | Chimerix to Present at Cowen and Company 39th Annual Health Care Conference

2019-02-26 08:00:00 | Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019

2019-02-22 08:00:00 | Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study

2019-02-14 08:15:22 | Chimerix filing reveals ex-CEO's severance package after sudden resignation

2019-02-11 07:55:00 | New Research Coverage Highlights United Parcel Service, Healthcare Trust of America, CommVault, SPX FLOW, Chimerix, and International Speedway — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-06 14:20:49 | Sudden Departure: Chimerix CEO, board member resigns

2019-02-06 08:00:00 | Chimerix Announces Management Transition

2019-01-30 11:51:55 | What Type Of Shareholder Owns Chimerix, Inc.’s NASDAQ:CMRX?

2019-01-24 10:17:03 | Will Overall Growth Aid Thermo Fisher's TMO Q4 Earnings?

2019-01-24 10:03:03 | Can Solid Consumables Drive Illumina's ILMN Q4 Earnings?

2019-01-18 06:36:11 | What Lies Ahead for Abbott ABT Stock This Earnings Season?

2019-01-17 09:38:02 | 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

2019-01-04 07:30:00 | Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-27 09:23:36 | Stocks down in December for pharma firms in the Triangle

2018-12-22 04:43:29 | Should You Avoid Chimerix Inc CMRX?

2018-12-18 08:35:01 | 5 Beaten-Down Medical Product Stocks to Rebound in 2019

2018-12-12 11:26:38 | Is Chimerix, Inc. NASDAQ:CMRX Overpaying Its CEO?

2018-12-03 07:55:00 | New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

2018-11-08 07:44:33 | Chimerix: 3Q Earnings Snapshot

2018-11-08 07:00:00 | Chimerix Announces Third Quarter 2018 Financial Results

2018-11-07 08:14:16 | Chimerix to Present at the Stifel 2018 Healthcare Conference

2018-11-05 14:29:22 | The most valuable public companies in the Triangle Slideshow

2018-11-01 08:00:00 | Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018

2018-10-27 13:00:00 | Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018

2018-10-24 07:25:00 | Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology — Future Expectations, Projections Moving into 2018

2018-10-11 16:01:00 | Chimerix to Host Annual Investor Update on October 17, 2018

2018-10-11 13:23:06 | How Should You Think About Chimerix Inc’s NASDAQ:CMRX Risks?

2018-10-05 07:00:00 | Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek

2018-10-04 07:00:00 | Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

2018-09-26 07:30:00 | Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference

2018-09-04 14:38:20 | Inside The List: Highest-Paid Public Company CEOs

2018-08-29 07:00:00 | Chimerix to Participate in September Investor Conferences

2018-08-28 07:30:00 | Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-08 09:50:01 | Chimerix CMRX Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 08:43:38 | Chimerix: 2Q Earnings Snapshot

2018-08-08 07:00:00 | Chimerix Announces Second Quarter 2018 Financial Results

2018-08-08 06:30:00 | Chimerix, Inc. to Host Earnings Call

2018-08-01 08:00:00 | Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018

2018-07-24 08:15:47 | ContraVir Stock Rose on Clinical Trial Progress Report

2018-06-29 07:35:00 | New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle Financial Partners, and Empire State Realty Trust — Factors of Influence, Major Initiatives and Sustained Production

2018-06-12 07:00:00 | Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus

2018-06-10 17:29:32 | The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

2018-06-08 14:17:22 | What new FDA designation means for Durham's Chimerix

2018-06-07 08:41:34 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-07 07:30:00 | Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

2018-06-05 17:29:33 | Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act PAHPA

2018-05-17 08:20:00 | Recent Analysis Shows Camden Property Trust, Biglari, Argan, Chimerix, Workhorse Group, and Magellan Midstream Partners Market Influences — Renewed Outlook, Key Drivers of Growth